Kopran Past Earnings Performance
Past criteria checks 5/6
Kopran has been growing earnings at an average annual rate of 6.5%, while the Pharmaceuticals industry saw earnings growing at 15.2% annually. Revenues have been growing at an average rate of 10.8% per year. Kopran's return on equity is 12.1%, and it has net margins of 9.3%.
Key information
6.5%
Earnings growth rate
3.9%
EPS growth rate
Pharmaceuticals Industry Growth | 17.5% |
Revenue growth rate | 10.8% |
Return on equity | 12.1% |
Net Margin | 9.3% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Kopran Limited's (NSE:KOPRAN) Share Price Boosted 28% But Its Business Prospects Need A Lift Too
Sep 14Kopran (NSE:KOPRAN) Has Announced A Dividend Of ₹3.00
Aug 20Insufficient Growth At Kopran Limited (NSE:KOPRAN) Hampers Share Price
Jul 31Does Kopran (NSE:KOPRAN) Have A Healthy Balance Sheet?
Jun 12Here's Why Kopran (NSE:KOPRAN) Has A Meaningful Debt Burden
Jan 05Here's Why Kopran (NSE:KOPRAN) Has A Meaningful Debt Burden
Jun 03Kopran's (NSE:KOPRAN) Dividend Will Be Increased To ₹3.00
Jul 14Here's Why I Think Kopran (NSE:KOPRAN) Might Deserve Your Attention Today
Nov 25Should You Be Adding Kopran (NSE:KOPRAN) To Your Watchlist Today?
Jun 10These 4 Measures Indicate That Kopran (NSE:KOPRAN) Is Using Debt Safely
Mar 21If You Had Bought Kopran (NSE:KOPRAN) Stock A Year Ago, You Could Pocket A 327% Gain Today
Feb 14Kopran Limited's (NSE:KOPRAN) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?
Jan 24Is Kopran (NSE:KOPRAN) A Risky Investment?
Dec 20Introducing Kopran (NSE:KOPRAN), The Stock That Soared 338% In The Last Year
Nov 15Kopran Limited's (NSE:KOPRAN) Stock Is Going Strong: Is the Market Following Fundamentals?
Oct 11Is Kopran (NSE:KOPRAN) Using Too Much Debt?
Sep 07Kopran Limited's (NSE:KOPRAN) Shares Not Telling The Full Story
Jul 31Calculating The Fair Value Of Kopran Limited (NSE:KOPRAN)
Jul 13Revenue & Expenses Breakdown
How Kopran makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 6,370 | 593 | 530 | 0 |
31 Mar 24 | 6,146 | 510 | 543 | 0 |
31 Dec 23 | 5,789 | 404 | 555 | 0 |
30 Sep 23 | 5,780 | 315 | 536 | 0 |
30 Jun 23 | 5,424 | 224 | 526 | 0 |
31 Mar 23 | 5,510 | 272 | 519 | 0 |
31 Dec 22 | 5,434 | 367 | 486 | 0 |
30 Sep 22 | 5,172 | 498 | 487 | 0 |
30 Jun 22 | 5,278 | 623 | 466 | 0 |
31 Mar 22 | 4,775 | 610 | 449 | 0 |
31 Dec 21 | 4,746 | 586 | 440 | 0 |
30 Sep 21 | 4,548 | 542 | 416 | 0 |
30 Jun 21 | 4,463 | 537 | 409 | 0 |
31 Mar 21 | 4,918 | 616 | 398 | 0 |
31 Dec 20 | 4,393 | 514 | 392 | 0 |
30 Sep 20 | 4,274 | 420 | 389 | 0 |
30 Jun 20 | 3,962 | 310 | 364 | 0 |
31 Mar 20 | 3,595 | 210 | 394 | 0 |
31 Dec 19 | 3,718 | 239 | 410 | 0 |
30 Sep 19 | 3,771 | 284 | 411 | 0 |
30 Jun 19 | 3,815 | 271 | 405 | 0 |
31 Mar 19 | 3,579 | 240 | 397 | 0 |
31 Dec 18 | 3,558 | 215 | 378 | 0 |
30 Sep 18 | 3,447 | 204 | 367 | 0 |
30 Jun 18 | 3,240 | 206 | 363 | 0 |
31 Mar 18 | 3,133 | 205 | 347 | 0 |
31 Dec 17 | 3,113 | 262 | 375 | 0 |
30 Sep 17 | 2,943 | 237 | 363 | 0 |
30 Jun 17 | 2,977 | 237 | 366 | 0 |
31 Mar 17 | 3,188 | 199 | 338 | 0 |
31 Dec 16 | 2,930 | 197 | 313 | 0 |
30 Sep 16 | 2,920 | 130 | 319 | 0 |
30 Jun 16 | 2,950 | 122 | 303 | 0 |
31 Mar 16 | 2,963 | 107 | 304 | 0 |
31 Mar 15 | 3,257 | -391 | 314 | 0 |
31 Mar 14 | 3,028 | 172 | 456 | 0 |
Quality Earnings: KOPRAN has high quality earnings.
Growing Profit Margin: KOPRAN's current net profit margins (9.3%) are higher than last year (4.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: KOPRAN's earnings have grown by 6.5% per year over the past 5 years.
Accelerating Growth: KOPRAN's earnings growth over the past year (164.5%) exceeds its 5-year average (6.5% per year).
Earnings vs Industry: KOPRAN earnings growth over the past year (164.5%) exceeded the Pharmaceuticals industry 19.2%.
Return on Equity
High ROE: KOPRAN's Return on Equity (12.1%) is considered low.